Characterizing Differences in Endolymphatic Hydrops Signatures Among Meniere’s Disease Patients with and Without Migraine
Medical Sciences · 2026
DOI: 10.3390/medsci14010029 ↗Kurz gefasst
Fachartikel in der Zeitschrift Medical Sciences, 2026. Verfasst von Yoshiyuki Sasano und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Otolaryngology, University of Miami Miller School of Medicine, Miami, FL 33136, USA. Hauptthemen laut MEDLINE: Meniere Disease, Endolymphatic Hydrops, Migraine Disorders. Die Arbeit nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background/Objectives: Migraine is frequently comorbid with Meniere’s disease, which may complicate interpretation of inner ear imaging and clinical diagnosis. While endolymphatic hydrops has been studied in Meniere’s disease and vestibular migraine separately, comparative imaging data for Meniere’s disease patients with and without migraine remain limited.
Methods
We retrospectively analyzed 78 patients with definite Meniere’s disease who underwent endolymphatic contrast-enhanced MRI (HYbriD of Reversed image of Positive endolymph signal and native image of positive perilymph signal; or “HYDROPS”). Patients were classified as Meniere’s disease only group (n = 56), or Meniere’s disease with migraine (n = 22). The degree of endolymphatic hydrops (negative, mild, or significant) was assessed separately in the inner ear, the cochlea, and the vestibule.
Results
In Meniere’s disease group, the affected ear consistently showed higher rates of significant endolymphatic hydrops compared to the healthy ear across the inner ear, cochlea, and vestibule (p < 0.01). In contrast, Meniere’s disease with migraine group showed no significant interaural differences. Meniere’s disease with migraine group showed a significantly higher frequency of significant endolymphatic hydrops in the healthy cochlea (p < 0.01). Similar patterns were observed in the inner ear (p < 0.025) and vestibule (p = 0.05), although these differences did not reach statistical significance. Bilateral hydrops was significantly more frequent in Meniere’s disease with migraine group than in Meniere’s disease group among all regions investigated (p < 0.05).
Conclusions
Meniere’s disease patients with migraine exhibit a distinct endolymphatic hydrops pattern, characterized by bilateral or symmetrical hydrops and involvement of the healthy ear. These findings suggest migraine-related mechanisms may contribute to endolymphatic hydrops, and bilateral endolymphatic hydrops on endolymphatic contrast-enhanced MRI in suspected Meniere’s disease cases should prompt consideration of comorbid migraine, in addition to bilateral Meniere’s disease or asymptomatic hydrops.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Otolaryngology, University of Miami Miller School of Medicine, Miami, FL 33136, USA.
- Department of Otolaryngology, St. Marianna University School of Medicine, Kawasaki 216-8511, Kanagawa, Japan.
ORCID-Profile: Yoshiyuki Sasano, Fumihiro Mochizuki, Yusuke Ito, Manabu Komori
Zitieren
APA
Sasano, Y., Mochizuki, F., Ito, Y., Williams, E., Koizuka, I., Hoffer, M. E., & Komori, M. (2026). Characterizing Differences in Endolymphatic Hydrops Signatures Among Meniere’s Disease Patients with and Without Migraine. Medical Sciences. https://doi.org/10.3390/medsci14010029
Vancouver
Sasano Y, Mochizuki F, Ito Y, Williams E, Koizuka I, Hoffer ME, et al. Characterizing Differences in Endolymphatic Hydrops Signatures Among Meniere’s Disease Patients with and Without Migraine. Medical Sciences. 2026. doi:10.3390/medsci14010029
BibTeX
@article{Sasano2026,
author = {Sasano, Yoshiyuki and Mochizuki, Fumihiro and Ito, Yusuke and Williams, Erin and Koizuka, Izumi and Hoffer, Michael E and Komori, Manabu},
title = {Characterizing Differences in Endolymphatic Hydrops Signatures Among Meniere’s Disease Patients with and Without Migraine},
journal = {Medical Sciences},
year = {2026},
doi = {10.3390/medsci14010029}
}
EUVIMED